PALISADE BIO, INC. Selling, General and Administrative Expense
PALISADE BIO, INC. (PALI) reported Selling, General and Administrative Expense of $256.00 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2013-03-15
- PALISADE BIO, INC. selling, general and administrative expense for fiscal 2012 was $256.00K, a 0.00% change from fiscal 2011.
- PALISADE BIO, INC. selling, general and administrative expense for fiscal 2011 was $256.00K.
| Period end | Selling, General and Administrative Expense 12 month |
|---|---|
| 2012-12-31 | $256.00K 10-K · filed 2013-03-15 |
| 2011-12-31 | $256.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |